This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of participants with unresectable Hepatocellular Carcinoma (HCC, a.k.a. liver cancer).

Eye90 is comprised of tiny glass beads containing yttrium-90 (Y90), a radioactive material. The beads are delivered in and around the tumor(s) through a tiny catheter placed through the artery of the groin or wrist and into one or more branches of the artery of the liver under x-ray camera guidance.

Eye90 is a new medical device that resembles and aims to improve upon two devices that have been used safely worldwide over the last 20 years. While these older devices, (SIR-Spheres and TheraSphere), are approved by the U.S. Food and Drug Administration (FDA), Eye90 is considered investigational, which means it is not yet approved by the FDA.

Total study participation is expected to last 1 year. Participants will be followed clinically and with imaging during this time and then will continue to receive standard of care after study participation.